Therapeutic Projects

With respect to therapeutic projects the Neuroallianz is currently focusing on the development of small molecules. Therefore projects have been selected for which targets on a molecular level are already identified. One of these projects is planned to start to clinical development in the course of this initiative. Moreover, the Neuroallianz pipeline includes projects in which - as a first step - potential therapeutic targets of neurodegenerative diseases are identified.

List of therapeutic Neuroallianz projects:

  • T3 (T3, T3B, T3B): New concept for the treatment of neuroinflammatory and neurodegenerative diseases
  • T6 B: Structural analysis of the serotonin transporter
  • T7 B: Optimization of P2X4-Receptor-Antagonists as therapeutics for neurodegenerative and neuroinflammatory diseases
  • T8 B: Treatment of neurodegenerative diseases/modulation of of oxidative stress
  • N2 (N2, N2B): Drug target identification through RNAi screening
  • N3 (N3, N3B): Identification of micro-RNAs and their target mRNAs and investigation of biochemical pathways and the in vitro phenotype of deregulated microRNAs in epilepsy
© Fotolia


To provide the German location of biotechnology and pharma industry with fresh impulsion, the German Federal Ministry for Education and Research (BMBF) started the pharma initiative "BioPharma: The Strategy Competition for Future Medicines". The Neuroallianz Consortium was nominated for this initiative.

The Neuroallianz Consortium has created a novel strategic partnership where various academic institutions and companies are working jointly on innovative diagnostic and therapeutic research projects. The aim is to efficiently transform research into benefits for the patients.

Main focuses are diagnostic and therapy of neurodegenerative diseases such as Parkinson's Disease, or Alzheimer's Dementia, and Epilepsy.

Duration: 2009 – 2018

Budget: 40 Mio. €